The National Institute for Health and Clinical Excellence (NICE) have announced their decision not to recommend the use of Tarceva (erlotinib) for the treatment of locally-advanced or metastatic non-small-cell lung cancer (NSCLC) in the National Health Service (NHS) in England and Wales. NICE’s Final Appraisal Determination (FAD) on Tarceva last week concluded that the drug [...]
Entries Tagged as 'Tarceva'
Market intelligence – when NICE is not so nice
April 29th, 2008 · No Comments · Roche, Tarceva, company news, competitive intelligence, market intelligence, market trends
Tags: